This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.

The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.

Even though RGTI stock has already seen an impressive 1,300% increase over the past twelve months, the question persists: ...

You should consider the Invesco S&P 500 Equal Weight Health Care ETF (RSPH), a passively managed exchange traded fund launched on 11/01/2006. An increasingly popular option among retail and ...

The S&P 500 slid 0.3% on Friday, July 11, 2025, retreating from record levels after President Trump announced a 35% tariff on ...

The S&P 500 ticked 0.1% on Monday, July 14, 2025, as trade policy remained in the spotlight to kick off a week that also ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...